These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 23276170)
1. Food and Drug Administration approval of laboratory tests. Allen TC Arch Pathol Lab Med; 2013 Jan; 137(1):13-8. PubMed ID: 23276170 [No Abstract] [Full Text] [Related]
2. More than just an oncogene translocation and a kinase inhibitor: Kevin's story. Costa DB J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391 [No Abstract] [Full Text] [Related]
3. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764 [TBL] [Abstract][Full Text] [Related]
4. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824 [No Abstract] [Full Text] [Related]
5. FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC. Wright KM Oncology (Williston Park); 2020 Oct; 34(10):406-406;431. PubMed ID: 33058106 [TBL] [Abstract][Full Text] [Related]
6. [A new target in non-small cell lung cancer: ROS1 fusion gene]. Cai WJ; Su B Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):1-4. PubMed ID: 23648291 [No Abstract] [Full Text] [Related]
7. Drug development and FDA approval, 1938-2013. Darrow JJ; Kesselheim AS N Engl J Med; 2014 Jun; 370(26):e39. PubMed ID: 24963591 [No Abstract] [Full Text] [Related]
10. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Rodig SJ; Shapiro GI Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129 [TBL] [Abstract][Full Text] [Related]
11. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. Mello MM; Studdert DM; Brennan TA N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413 [No Abstract] [Full Text] [Related]
12. Food and Drug Administration centennial: recognizing the guardians of our drug supply. Beary JF Arthritis Rheum; 2006 Oct; 54(10):3374. PubMed ID: 17009312 [No Abstract] [Full Text] [Related]
13. Access before approval--a right to take experimental drugs? Okie S N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545 [No Abstract] [Full Text] [Related]
14. Cancer drug approval in the United States, Europe, and Japan. Milsted RA Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686 [No Abstract] [Full Text] [Related]
15. Targeting anaplastic lymphoma kinase in lung cancer. Shaw AT; Solomon B Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922 [TBL] [Abstract][Full Text] [Related]
16. New targets in advanced NSCLC: EML4-ALK. Crystal AS; Shaw AT Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126 [TBL] [Abstract][Full Text] [Related]
17. Food and Drug Administration: 100 years of protection. Mosocco DJ Home Healthc Nurse; 2007 Mar; 25(3):148-50. PubMed ID: 17353704 [No Abstract] [Full Text] [Related]
18. Discovery of drug resistance biomarker could improve cancer treatment. Pharmacogenomics; 2013 Jan; 14(2):125. PubMed ID: 23447824 [No Abstract] [Full Text] [Related]
19. Food and Drug Administration Drug Approval Process: A History and Overview. Williams CT Nurs Clin North Am; 2016 Mar; 51(1):1-11. PubMed ID: 26897420 [TBL] [Abstract][Full Text] [Related]
20. Sure cure: public policy on drug efficacy before 1962. Swann JP Publ Am Inst Hist Pharm; 1997; 16():223-61. PubMed ID: 11619897 [No Abstract] [Full Text] [Related] [Next] [New Search]